Robotic systems were developed to overcome limitations of laparoscopic surgery with its mechanical advantages. Along with the technical advances, robotic gastrectomy for gastric cancer is increasing. However, the evidence regarding safety and efficacy for robotic gastrectomy for gastric cancer is not mature yet. Although studies are limited, it is evident that robotic gastrectomy has a longer operation and less blood loss compared with laparoscopic gastrectomy. Studies revealed long-term oncological outcomes after robotic gastrectomy was comparable to those after laparoscopic gastrectomy. Taken together, robotic gastrectomy with systemic lymph node dissection is suggested as a safe procedure with equivalent short- and long-term oncologic outcomes to either laparoscopic or open gastrectomy for the surgical treatment of gastric cancer. However, high cost is the most significant barrier to justify robotic surgery as a routine and standard treatment for patients with gastric cancer. In the meanwhile, robotic surgery will be expansively used as long as technologic developments continue.
Bibliographical noteFunding Information:
This study was supported by a grant from the Investigator Sponsored Research Program (ISR-2017–10924), Covidien Private Limited (Medtronic). This funding source had no role in the design of this manuscript and will not have any role during its execution, data analyses, and interpretation.
Dr. Hyung WJ reports receiving research grants from the Medtronic and GC Pharma and is the chief executive officer of Hutom and holding its stocks. He provided consultancy services to Ethicon and Verb Surgical outside the submitted work. He received lecture fees from Stryker. Dr. Kin YM reports no conflict of interest.
© 2021, Italian Society of Surgery (SIC).
All Science Journal Classification (ASJC) codes